Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Inventory (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Inventory data on record, last reported at $38.1 million in Q3 2025.

  • For Q3 2025, Inventory changed 0.05% year-over-year to $38.1 million; the TTM value through Sep 2025 reached $38.1 million, changed 0.05%, while the annual FY2024 figure was $35.6 million, 9.98% up from the prior year.
  • Inventory reached $38.1 million in Q3 2025 per COLL's latest filing, up from $35.6 million in the prior quarter.
  • Across five years, Inventory topped out at $80.1 million in Q1 2022 and bottomed at $15.5 million in Q1 2021.
  • Average Inventory over 5 years is $37.4 million, with a median of $32.9 million recorded in 2023.
  • Peak YoY movement for Inventory: skyrocketed 417.14% in 2022, then tumbled 66.53% in 2023.
  • A 5-year view of Inventory shows it stood at $17.4 million in 2021, then surged by 167.34% to $46.5 million in 2022, then plummeted by 30.47% to $32.3 million in 2023, then increased by 9.98% to $35.6 million in 2024, then increased by 7.01% to $38.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $38.1 million in Q3 2025, $35.6 million in Q4 2024, and $38.0 million in Q3 2024.